909 related articles for article (PubMed ID: 29062229)
1. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
[TBL] [Abstract][Full Text] [Related]
3. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
4. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
Kupczyk M; Kuna P
Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
[TBL] [Abstract][Full Text] [Related]
5. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Dean J; Panainte C; Khan N; Singh D
Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Dhungana S; Criner GJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
[TBL] [Abstract][Full Text] [Related]
8. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
10. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
11. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
[TBL] [Abstract][Full Text] [Related]
13. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
15. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
Singh D; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
[TBL] [Abstract][Full Text] [Related]
17. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
19. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
Singh D
Expert Opin Pharmacother; 2018 Aug; 19(11):1279-1287. PubMed ID: 29985096
[TBL] [Abstract][Full Text] [Related]
20. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]